Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_assertion type Assertion NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_head.
- NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_assertion description "[Current HER2-directed therapies confer limited clinical benefits and most patients experience progressive disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_provenance.
- NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_assertion evidence source_evidence_literature NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_provenance.
- NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_assertion SIO_000772 20179231 NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_provenance.
- NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_assertion wasDerivedFrom befree-2016 NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_provenance.
- NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_assertion wasGeneratedBy ECO_0000203 NP795645.RAJ0ML9aABLsiiOTn_CnQIWlmPS79Lw0oaEqnUlgYTgcI130_provenance.